Jenis
obat diabetes tipe 2 bisa bermanfaat bagi pasien kanker kepala dan leher
Date:
June 4, 2016
Source:
University of Cincinnati Academic Health Center
Summary:
Para peneliti telah menemukan bahwa menambahkan peningkatan dosis dari metformin disetujui pada obat diabetes tipe 2 , untuk kemoterapi dan pengobatan radiasi rejimen pada pasien kanker kepala dan leher tidak ditoleransi jika meningkat terlalu cepat, tetapi memungkinkan eskalasi lebih lambat yang dapat bermanfaat.
Para peneliti telah menemukan bahwa menambahkan peningkatan dosis dari metformin disetujui pada obat diabetes tipe 2 , untuk kemoterapi dan pengobatan radiasi rejimen pada pasien kanker kepala dan leher tidak ditoleransi jika meningkat terlalu cepat, tetapi memungkinkan eskalasi lebih lambat yang dapat bermanfaat.
............................
Researchers at the University of Cincinnati (UC) College of Medicine have found
that adding increasing doses of an approved Type 2 diabetes drug, metformin, to
a chemotherapy and radiation treatment regimen in head and neck cancer patients
is not well tolerated if escalated too quickly, but allowing slower escalation
could be beneficial.
Para peneliti di University of Cincinnati (UC) College of Medicine telah menemukan bahwa menambahkan peningkatan dosis disetujui obat diabetes yipe 2, metformin, untuk kemoterapi dan pengobatan radiasi rejimen pada pasien kanker kepala dan leher tidak ditoleransi dengan baik jika meningkat terlalu cepat, tapi memungkinkan eskalasi lebih lambat yang dapat bermanfaat.
Temuan ini dipresentasikan melalui poster 4 Juni di 2016 American Society of Clinical Oncology (ASCO) Annual Meeting: Collective Wisdom , yang diadakan 03-07 Juni di Chicago.
Trisha Wise-Draper, MD, PhD, asisten profesor di Divisi Hematologi Onkologi di UC College of Medicine, anggota dari Cancer Center Cincinnati dan UC Cancer Institute dan peneliti utama pada studi ini, mengatakan studi retrospektif telah menunjukkan hasil yang lebih baik pada tumor diobati dengan kemoterapi dan radiasi jika mereka juga pada metformin untuk diabetes.
............................
SILAHKAN MENGGUNAKAN
" MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
DISAMPING KANAN INI.............
PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS
.................
........................................
........................................
........................................
........................................
T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA
More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
..................................
..................................
..................................
KSE – KOMUNITAS SATWA EKSOTIK –
EXOTIC PETS
COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
KSE = KOMUNITAS SATWA EKSOTIK
MENGATASI KENDALA MINAT DAN JARAK
KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com
GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI : 08995557626
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
FAST RESPON :
08995557626/764047D2
........Komunitas T-REC semarang,komunitas
reptil tugumuda reptiles community semarang,komunitas reptil tugumuda
semarang,komunitas semarang,komunitas reptil semarang.............kenali dan
dalami satwa dan reptil dengan bergabung
bersama kami,hubungi 08995557626 / 764047D2.....
........Komunitas KSE ,komunitas satwa eksotik
,komunitas satwa.............kenali dan dalami satwa dan reptil dengan bergabung bersama kami,hubungi
08995557626 / 764047D2.....
.............................
...........................
Type 2 diabetes
drug could be beneficial for head and neck cancer patients
Date:
June 4, 2016
Source:
University of Cincinnati Academic Health Center
Summary:
Researchers have found
that adding increasing doses of an approved Type 2 diabetes drug, metformin, to
a chemotherapy and radiation treatment regimen in head and neck cancer patients
is not well tolerated if escalated too quickly, but allowing slower escalation
could be beneficial.
............................
Researchers at the University of Cincinnati (UC) College of Medicine have
found that adding increasing doses of an approved Type 2 diabetes drug,
metformin, to a chemotherapy and radiation treatment regimen in head and neck
cancer patients is not well tolerated if escalated too quickly, but allowing
slower escalation could be beneficial.
These findings are
being presented via poster June 4 at the 2016 American Society of Clinical
Oncology (ASCO) Annual Meeting: Collective Wisdom, being held June 3-7 in
Chicago.
Trisha Wise-Draper,
MD, PhD, assistant professor in the Division of Hematology Oncology at the UC
College of Medicine, a member of both the Cincinnati Cancer Center and UC
Cancer Institute and principal investigator on this study, says retrospective
studies have shown improved outcomes in tumors treated with chemotherapy and
radiation if they were also on metformin for diabetes.
"In head and neck
squamous cell carcinoma, which develops in the mucous membranes of the mouth,
nose and throat, diabetic patients taking a medication called metformin had
better overall survival compared to those not on metformin when also treated
with chemotherapy and radiation," she says. "Additionally, pancreatic
cancer patients treated with chemotherapy and metformin required higher doses
of metformin--1,000 milligrams twice a day--to experience positive results.
"In basic science
studies, metformin has been shown to stop mTOR, a molecular pathway present and
active in this type of head and neck cancer, and pretreatment with metformin
resulted in a decrease in the occurrence of oral cavity tumors in animal models.
In this study, we wanted to see if the combination of escalating doses of
metformin with the chemotherapy agent cisplatin and radiation for head and neck
cancer tumors in non-diabetic patients would be effective."
Wise-Draper says that
metformin, which is an approved Type 2 diabetes medication, was provided by
their investigational pharmacy. Metformin was administered orally in escalating
doses for 7 to 14 days prior to starting the cisplatin and radiation and
continued throughout standard treatment. Blood samples were collected before
and after metformin treatment as well as during chemotherapy. Flow cytometry, a
technique used to count cells, was used to detect the percent of circulating
immune activated cells, and clinical laboratory tests including glucose, B12
and C-peptide (an amino acid that is important for controlling insulin) were
performed.
"This is part of
an ongoing clinical trial," says Wise-Draper. "We found that eight
patients with advanced head and neck cancer have been enrolled so far; we plan
to have 30 total. Due to the relatively quick escalation of metformin, the
patients' tolerance was poor with higher doses of metformin when initiated 7
days prior to their chemotherapy and radiation therapy regimen.
"Therefore, the
protocol was modified to allow slower escalation over 14 days. The most common
toxicities observed included nausea (71 percent of patients) and vomiting (43
percent of patients), increase in creatinine (57 percent of patients),
decreased white blood cell count (43 percent of patients) and pain when
swallowing (43 percent of patients) with only nausea being directly attributed
to metformin and the rest attributed to cisplatin and radiation."
She adds that there
wasn't a substantial change in T cell or glucose levels with administration of
metformin in the small sample of patients but that there were increased
C-peptide levels in response to metformin administration.
"These results
show that the combination of metformin and cisplatin and radiation was poorly
tolerated when metformin was escalated quickly. However, there has been no
significant increase in side effects thus far with the addition of
metformin," Wise-Draper says. "The trial is continuing with
escalation of metformin over a longer period of time to provide more data; we
will also try to increase our sample size."
Story Source:
The above post is
reprinted from materials provided byUniversity of Cincinnati Academic
Health Center. Note: Materials may be edited for content and length.